In mouse models, interleukin-6 (IL-6) is elevated in male HCC, leading to activation of signal transduction and activator of transcription 3 (STAT3), which upregulates AR85, and IL-6 has been suggested as a biomarker associated with worse outcomes in human HCC86. The gene discussed is IL6; the disease is hepatocellular carcinoma.